Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

For decades, research into cancer biology focused on the involvement of protein-coding
genes. Only recently was it discovered that an entire class of molecules, termed non-coding …

The discovery of drivers of cancer has traditionally focused on protein-coding genes,,–. Here
we present analyses of driver point mutations and structural variants in non-coding regions …

We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …

Cancer is driven by genetic change, and the advent of massively parallel sequencing has
enabled systematic documentation of this variation at the whole-genome scale,–. Here we …

Tumour formation involves random mutagenic events and positive evolutionary selection
acting on a subset of such events, referred to as driver mutations. A decade of careful …

Cancer stem cells (CSCs), which have the potential for self-renewal, differentiation and de-
differentiation, undergo epigenetic, epithelial-mesenchymal, immunological and metabolic …

Long noncoding RNA (lncRNA) molecules are some of the newest and least understood
players in gene regulation. Hence, we need good model systems with well-defined RNA and …

Explosive advances in next‐generation sequencer (NGS) and computational analyses have
enabled exploration of somatic protein‐altered mutations in most cancer types, with coding …

INTRODUCTION Extensive tumor sequencing efforts have transformed the way in which
cancer driver genes are identified. Appropriate statistical modeling is crucial for …